Buy Aurobindo Pharma, target price Rs 564: BNP Paribas Securities

BNP Paribas Securities has buy call on Aurobindo Pharma with a target price of Rs 564.The current market price of Aurobindo Pharma is Rs 433.4.

Aurobindo Pharma, incorporated in the year 1986, is a Large Cap company (having a market cap of Rs 25678.76 Crore) operating in Pharmaceuticals sector.

Aurobindo Pharma key Products/Revenue Segments include Pharmaceuticals, Sale of services, Export Incentives and Scrap for the year ending 31-Mar-2022.


Financials
For the quarter ended 30-09-2022, the company has reported a Consolidated Total Income of Rs 5796.56 Crore, down -7.65 % from last quarter Total Income of Rs 6276.54 Crore and down -4.01 % from last year same quarter Total Income of Rs 6038.50 Crore. Company has reported net profit after tax of Rs 411.60 Crore in latest quarter.

The company’s top management includes Mr.K Ragunathan, Mr.K Nithyananda Reddy, Mr.P Sarath Chandra Reddy, Dr.M Sivakumaran, Mr.M Madan Mohan Reddy, Mr.P V Ramprasad Reddy, Mrs.Savita Mahajan, Mr.Girish P Vanvari, Dr.(Mrs.)Avnit Bimal Singh. Company has BSR & Associates LLP as its auditors. As on 30-09-2022, the company has a total of 59 Crore shares outstanding.

Promoter/FII Holdings
Promoters held 51.83 per cent stake in the company as of 30-Sep-2022, while FIIs owned 22.43 per cent, DIIs 16.55 per cent.